Attorney Docket No.: 47259-5001-00 US (223490)

Application No.: 10/573,821

Response to Office Action mailed: October 1, 2010

Response filed: January 28, 2011

Page 2

AMENDMENTS TO THE CLAIMS

The following listing of the claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims:

Claims 1-48. (Canceled).

Claim 49. (Currently Amended): A process for cleaving a polypeptide comprising cleaving the polypeptide with an *E. coli* OmpT protease 97th amino acid variant,

wherein the 97th amino acid from the N-terminus of the E. coli OmpT protease 97th amino acid variant is alanine; leucine, phenylalanine; methionine, serine, threonine, eysteine, asparagine, glutamine, glutamic acid or histidine,

wherein the polypeptide comprises a cleavage site that is a peptide bond between a P1 position and a P1' position, and

wherein the P1 position is arginine or lysine and the P1' position is an amino acid other than arginine or lysine;

- (1) serine or alanine when the 97th amino acid from the N-terminus of the *E. coli* OmpT protease 97th amino acid variant is leucine;
- (2) phenylalanine, alanine, serine, cysteine, or tyrosine when the 97th amino acid from the N-terminus of the E. coli OmpT protease 97th amino acid variant is methionine: or
- (3) alanine, valine, isoleucine, methionine, serine, threonine, cysteine, or asparagine when the 97th amino acid from the N-terminus of the E. coli OmpT protease 97th amino acid variant is histidine.

Claim 50. (Canceled).

Attorney Docket No.: 47259-5001-00 US (223490) Application No.: 10/573,821

Response to Office Action mailed: October 1, 2010

Response filed: January 28, 2011

Page 3

Claim 51. (Currently Amended): The process of claim 49, wherein the amino acid

sequence from a P10 position to a P3 position consists of a single basic amino acid or two or three consecutive basic amino acids are situated in the amino acid sequence from a P10 position

to a P3 position.

Claim 52. (Previously Presented): The process of claim 51, wherein the basic amino

acids are arginine and/or lysine.

Claim 53. (Previously Presented): The process of claim 52, wherein the basic amino

acids are arginine.

Claim 54. (Previously Presented): The process of claim 49,

wherein the polypeptide is a fusion protein comprising a protecting peptide and a target

peptide,

wherein the C-terminus of the protecting peptide is the P1 position and the N-terminus of

the target peptide is the P1' position,

wherein the fusion protein is produced by expressing a gene encoding the fusion protein

in a host cell, and

wherein cleavage of the fusion protein liberates the target peptide.

Claim 55. (Currently Amended): The method process of claim 54, wherein a single

basic amino acid or two or three consecutive basic amino acids are situated in the amino acid

sequence from a P10 position to a P3 position.

Claim 56. (Previously Presented): The process of claim 54, wherein the E. coli OmpT

protease 97th amino acid variant is produced by expressing a gene encoding the E. coli OmpT

protease 97th amino acid variant in said host cell.

DC01/2580073.1

Attorney Docket No.: 47259-5001-00 US (223490)

Application No.: 10/573,821

Response to Office Action mailed: October 1, 2010

Response filed: January 28, 2011

Page 4

Claims 57-58. (Canceled).

Claim 59. (Currently Amended): The process of claim 49, wherein two or three consecutive basic amino acids are situated between the P10 and P3 positions in the polypeptide.

Claim 60. (Currently Amended): The process of claim 59, wherein three consecutive basic amino acids are situated between the P5 and P3 positions in the polypeptide.

Claim 61. (Currently Amended): The process of claim 49, wherein the amino acid sequence from the P5 to P1 positions in the polypeptide is Arg-Arg-Arg-Ala-Arg (SEQ ID NO: 11).

Claim 62. (Currently Amended): The process of claim 49, wherein the amino acid sequence from the P7 to P1 positions in the polypeptide is Asp-Ala-Arg-Arg-Arg-Ala-Arg (SEQ ID NO: 12).

Claims 63-66. (Canceled).

Claim 67. (Currently Amended): The process of claim 54, wherein the target peptide is eemposed consists of between 22 and 45 amino acid residues.

Claim 68. (Previously Presented): The process of claim 67, wherein the target peptide is adrenocorticotropic hormone (1-24), motilin, or calcitonin precursor.